CTRI/2023/11/059748尚未招募Unknown
Outcomes of Breast and Ovarian cancer patients with HRD/BRCA gene alterations treated with PARP inhibitors at a tertiary care hospital in Eastern India. - BROCA-PI
INSTITUTE OF MEDICAL SCIENCES AND SUM HOSPITA0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Newly diagnosed Breast and ovarian cancer patients greater than 18 years with HRD/BRCA gene alterations registered in the department of Medical Oncology, IMS and SUM hospital
排除标准
- •1. Patients less than 18 years of age
- •2. Patients not meeting the above-mentioned criteria
- •3. Patients or patient relatives who do not consent to the testing
- •4. Patients with BRCA1 and/or BRCA2 mutations that are considered to be non-detrimental (eg, Variants of uncertain clinical significance ? or Variant of unknown significance ? or Variant, favor polymorphism ? or benign polymorphism, ? etc).
研究者
相似试验
已完成
3 期
Phase III Randomized Trial of Maintenance Pegylated Liposomal Doxorubicin (PLD)/ Carboplatin versus without in Patients with Advanced Ovarian CancerAdvanced ovarian cancerCancer - Ovarian and primary peritonealACTRN12607000329460Chang Gung Memorial Hospital122
尚未招募
Unknown
A Study on Quality of Life assessment in Patients with Breast CancerCTRI/2024/06/068845ational Institute Of Siddha
已完成
不适用
Oncological outcome of patients with (low-risk) endometrial cancer undergoing laparotomy versus vaginal hysterectomy - a retrospective analysisC54.1EndometriumDRKS00009810niversitätsfrauenklinik am Klinikum Südstadt350
终止
不适用
Improving communication about treatment options for asymptomatic ovarian cancer patients with rising cancer antigen 125 (CA-125): A randomised controlled trial of a Decision AidCommunication about treatment options and decision making for women with asymptomatic ovarian cancer and rising CA-125 levels.Cancer - Ovarian and primary peritonealACTRN12609001035213Centre for Medical Psychology and Evidence-based Decision-making178
未知
不适用
PIVOTAL STUDY IN PATIENTS WITH BREAST CANCER TO INVESTIGATE THE EFFICACY AND SAFETY OF LA-EP2006 and NEULASTA ®PER-119-11Sandoz GmbH,